Lewis H. Titterton Jr., serving as a director at Anixa Biosciences Inc. (NASDAQ:ANIX), acquired 2,797 shares of the company's common stock on July 15, 2026. The transaction was executed at a price of $3.28 per share, resulting in a total investment value of $9,174. Following this acquisition, Mr. Titterton's direct ownership in Anixa Biosciences stands at 974,967 shares. The company's stock has appreciated to $3.50 since the transaction, reflecting an 8.7% gain over the preceding week. Despite this recent price movement, analysis from InvestingPro indicates that the company may be overvalued at its current trading levels.
Anixa Biosciences is actively advancing its clinical trial portfolio and intellectual property assets. The firm has administered the first dose to a patient in the highest cohort of its Phase 1 clinical trial for a CAR-T therapy designed to target recurrent ovarian cancer. This trial, taking place at Moffitt Cancer Center, is assessing the therapy's ability to target the follicle-stimulating hormone receptor on ovarian cancer cells. In parallel, Anixa has secured a South Korean patent for its breast cancer vaccine technology. This technology is licensed from Cleveland Clinic and provides intellectual property protection through 2040. Data presented at the New York Academy of Sciences symposium from the Phase 1 clinical trials demonstrated that the breast cancer vaccine met all major primary endpoints and was well tolerated at the maximum dose. The vaccine induced immune responses in 74% of the participants.
Financially, Anixa Biosciences reported a net loss of $2.5 million for the fiscal second quarter ending April 30, 2026. Operating activities generated negative cash flows during this period. However, the balance sheet shows the company holds more cash than debt, supported by a strong current ratio of 9.79, which contributes to a "GOOD" financial health rating. At the end of the quarter, Anixa maintained $13.7 million in cash and investments. H.C. Wainwright has reiterated a Buy rating for Anixa, establishing a price target of $7.00.